Recent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis
Eko Fuji Ariyanto,Ibnu Wijaya,Zaky Pradian,Agung Putri Bhaskara,Putri Halleyana Rahman,Nandina Oktavia
DOI: https://doi.org/10.2147/dmso.s463221
2024-04-30
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Eko Fuji Ariyanto, 1 Ibnu Wijaya, 2 Zaky Alif Pradian, 2 Agung Putri Mayasari Bhaskara, 2 Putri Halleyana Adrikni Rahman, 1 Nandina Oktavia 1 1 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia; 2 Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia Correspondence: Eko Fuji Ariyanto, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia, Email Atherosclerosis is one of the most dominant pathological processes responsible in cardiovascular diseases (CVD) caused by cholesterol accumulation accompanied by inflammation in the arteries which will subsequently lead to further complications, including myocardial infarction and stroke. Although the incidence of atherosclerosis is decreasing in some countries, it is still considered the leading cause of death worldwide. Atherosclerosis is a vascular pathological process that is chronically inflammatory and is characterized by the invasion of inflammatory cells and cytokines. Many reports have unraveled the pivotal roles of epigenetics such as DNA methylation, post-translational histone modifications, and non-coding RNAs (ncRNAs) in atherogenesis, which regulate the expression of numerous genes related to various responsible pathways. Many studies have been conducted to develop new therapeutical approaches based on epigenetic changes for combating atherosclerosis. This review elaborates on recent updates on the development of new atherosclerosis drugs whose mechanism of action is associated with the modulation of DNA methylation, posttranslational histone modifications, and ncRNA-based gene regulation. Keywords: atherosclerosis, DNA methylation, histone modifications, non-coding RNAs, pharmacotherapy Atherosclerosis, the most common underlying pathological condition in cardiovascular disease (CVD), is characterized by the accumulation of cholesterol and inflammation in major arteries, potentially leading to serious clinical outcomes like myocardial infarction (MI) and stroke. 1 In 2015, almost 17 million fatalities worldwide were attributed to CVD, accounting for 31% of all deaths. 2 This issue is particularly pronounced in many Asian countries, where annual death rates range from 103 to 366 per 100,000 adults. 3 Atherosclerosis develops in complicated steps that involve the buildup of lipoproteins like LDL in blood vessels, inflammation initiation, endothelial cell activation, immune cell adhesion, foam cell formation, and the eventual development of atherosclerotic plaques, some of which can become unstable and prone to rupture, leading to MI. 4–8 Epigenetics is defined as any chromatin change that alters DNA accessibility or chromatin structure to regulate gene expression which includes DNA methylation, posttranslational histone modification, and non-coding RNA (ncRNA) regulated gene expression. 9 Numerous studies suggested that pro-atherogenic factors like LDL cholesterol and oxidized LDL can permanently remodel the epigenome of innate immune system cells. 10 Although epigenetic changes are heritable, they can still be modified with the use of medication. 11 Many studies have been conducted to develop new therapeutic approaches based on epigenetic changes for combating atherosclerosis through various molecular pathways, so this review elaborates on recent updates on the development of new atherosclerosis drugs whose mechanism of action is associated with the modulation of DNA methylation, posttranslational histone modifications, and ncRNA-based gene regulation. Epigenetics is the study of changes in gene expression without changes in DNA sequence, which is related to changes in environmental cues, including lifestyle. 12,13 The first epigenetic mechanism is through changes in DNA methylation levels. The addition of methyl groups to CpG sites on the DNA reduces gene expression. 12 The second mechanism is through posttranslational modification which can take the form of adding acetyl, methyl, or other groups to histones. 14 Epigenetic regulation can also involve ncRNA, namely RNA that is produced from DNA transcription like other RNA but does not undergo translation into protein. 9 DNA methylation is the earliest and most widely studied epigenetic marker and involves the addition of a methyl group (-CH3) at position 5 of cytosine which binds to guanine via phosphate (CpG) to produce 5-methylcytosine. 15,16 In mammals, most CpG islands are found in promoters, gene areas that play a major role in the initiation of gene transcription. 17 Previous studies have shown that DNA methylation has various functions, such as mammalian embryonic developm -Abstract Truncated-
endocrinology & metabolism